Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy
Molecular Cancer · 2024
DOI: 10.1186/s12943-024-02027-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Cancer, 2024. Verfasst von Marc Zuckermann und 33 weiteren Autor:innen. Beteiligte Einrichtung: Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. m.zuckermann@kitz-heidelberg.de. Hauptthemen laut MEDLINE: Glioma, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, Brain Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Deutscher Akademischer Austauschdienst, National Cancer Institute.
Abstract (Originalsprache)
Background
Pediatric-type diffuse high-grade glioma (pHGG) is the most frequent malignant brain tumor in children and can be subclassified into multiple entities. Fusion genes activating the MET receptor tyrosine kinase often occur in infant-type hemispheric glioma (IHG) but also in other pHGG and are associated with devastating morbidity and mortality.
Methods
To identify new treatment options, we established and characterized two novel orthotopic mouse models harboring distinct MET fusions. These included an immunocompetent, murine allograft model and patient-derived orthotopic xenografts (PDOX) from a MET-fusion IHG patient who failed conventional therapy and targeted therapy with cabozantinib. With these models, we analyzed the efficacy and pharmacokinetic properties of three MET inhibitors, capmatinib, crizotinib and cabozantinib, alone or combined with radiotherapy.
Results
Capmatinib showed superior brain pharmacokinetic properties and greater in vitro and in vivo efficacy than cabozantinib or crizotinib in both models. The PDOX models recapitulated the poor efficacy of cabozantinib experienced by the patient. In contrast, capmatinib extended survival and induced long-term progression-free survival when combined with radiotherapy in two complementary mouse models. Capmatinib treatment increased radiation-induced DNA double-strand breaks and delayed their repair.
Conclusions
We comprehensively investigated the combination of MET inhibition and radiotherapy as a novel treatment option for MET-driven pHGG. Our seminal preclinical data package includes pharmacokinetic characterization, recapitulation of clinical outcomes, coinciding results from multiple complementing in vivo studies, and insights into molecular mechanism underlying increased efficacy. Taken together, we demonstrate the groundbreaking efficacy of capmatinib and radiation as a highly promising concept for future clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. m.zuckermann@kitz-heidelberg.de.
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, Heidelberg, Germany. m.zuckermann@kitz-heidelberg.de.
- Division of Pediatric Glioma Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany. m.zuckermann@kitz-heidelberg.de.
- Department of Developmental Neurobiology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA.
- Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA.
- Center for Pediatric Neurological Disease Research, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA.
Förderung
- NCI NIH HHS
- Deutscher Akademischer Austauschdienst
- National Cancer Institute
- National Brain Tumor Society
- Bundesministerium für Bildung und Forschung
- American Lebanese Syrian Associated Charities
- Musicians Against Childhood Cancer, USA
Zitieren
APA
Zuckermann, M., He, C., Andrews, J., Bagchi, A., Sloan-Henry, R., Bianski, B., Xie, J., Wang, Y., Twarog, N., Onar-Thomas, A., Ernst, K. J., Yang, L., Li, Y., Zhu, X., Ocasio, J. K., Budd, K. M., Dalton, J., Li, X., Chepyala, D., …, & Baker, S. J. (2024). Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy. Molecular Cancer. https://doi.org/10.1186/s12943-024-02027-6
Vancouver
Zuckermann M, He C, Andrews J, Bagchi A, Sloan-Henry R, Bianski B, et al. Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy. Molecular Cancer. 2024. doi:10.1186/s12943-024-02027-6
BibTeX
@article{Zuckermann2024,
author = {Zuckermann, Marc and He, Chen and Andrews, Jared and Bagchi, Aditi and Sloan-Henry, Roketa and Bianski, Brandon and Xie, Jia and Wang, Yingzhe and Twarog, Nathaniel and Onar-Thomas, Arzu and Ernst, Kati J and Yang, Lei and Li, Yong and Zhu, Xiaoyan and Ocasio, Jennifer K and Budd, Kaitlin M and Dalton, James and Li, Xiaoyu and Chepyala, Divyabharathi and Zhang, Junyuan and Xu, Ke and Hover, Laura and Roach, Jordan T and Chan, Kenneth Chun-Ho and Hofmann, Nina and McKinnon, Peter J and Pfister, Stefan M and Shelat, Anang A and Rankovic, Zoran and Freeman, Burgess B and Chiang, Jason and Jones, David T W and Tinkle, Christopher L and Baker, Suzanne J},
title = {Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy},
journal = {Molecular Cancer},
year = {2024},
doi = {10.1186/s12943-024-02027-6}
}
EUVIMED